FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1138-1139 April 13, 2000 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Lipscomb, G. H.

To the Editor: Autologous bone marrow transplantation has been a controversial treatment for metastatic breast cancer. Proponents of the procedure have pointed to studies indicating an increase in disease-free survival with this approach, whereas others have suggested that the improved survival has been due to patient selection.¹

From 1996 through 1998, the number of requests for autologous bone marrow transplantation for metastatic breast cancer received by Anthem Blue Cross increased from 64 per year to 83 per year. Two important events occurred in May 1999: the company expanded the indications for autologous bone marrow transplantation for metastatic breast cancer to . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.